Douglas Baker Net Worth

The estimated Net Worth of Douglas P Baker is at least $6.46 million dollars as of 5 October 2021. Mr. Baker owns over 14,000 units of OptimizeRx Corp stock worth over $253,315 and over the last 10 years he sold OPRX stock worth over $5,756,914. In addition, he makes $449,528 as Chief Financial Officer at OptimizeRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Baker OPRX stock SEC Form 4 insiders trading

Douglas has made over 36 trades of the OptimizeRx Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 14,000 units of OPRX stock worth $1,160,320 on 5 October 2021.

The largest trade he's ever made was exercising 17,421 units of OptimizeRx Corp stock on 3 June 2020 worth over $54,876. On average, Douglas trades about 7,145 units every 62 days since 2014. As of 5 October 2021 he still owns at least 34,796 units of OptimizeRx Corp stock.

You can see the complete history of Mr. Baker stock trades at the bottom of the page.

Douglas Baker biography

Douglas P. Baker CPA serves as Chief Financial Officer of the Company. Mr. Baker is a Certified Public Account with a Master’s Degree in Business Administration. He has extensive business experience including 9 years in public accounting with Plante Moran, four years as CFO of a privately held printing company, 5 years in a variety of divisional financial roles at MascoTech, Inc., a Fortune 500 automotive supplier, and from 1996 to 2014 as Chief Financial Officer of Applied Nanotech Holdings, Inc., (“APNT”) a publicly held nanotechnology research and licensing company. Mr. Baker was also a member of the Board of Directors of APNT from 2006 through 2014. He was a member of the Board Directors of Total Health Care, Inc., a Detroit based Health Maintenance Organization from 1987 through January 2020, including his latest role as Chairman of the Board, until it was acquired by Priority Health, a Michigan based HMO in January 2020. He became a member of the Priority Health Board in January 2020.

What is the salary of Douglas Baker?

As the Chief Financial Officer of OptimizeRx Corp, the total compensation of Douglas Baker at OptimizeRx Corp is $449,528. There are 5 executives at OptimizeRx Corp getting paid more, with Stephen Silvestro having the highest compensation of $1,210,200.

How old is Douglas Baker?

Douglas Baker is 63, he's been the Chief Financial Officer of OptimizeRx Corp since 2014. There are 5 older and 8 younger executives at OptimizeRx Corp. The oldest executive at OptimizeRx Corp is Gus Halas, 69, who is the Chairman of the Board.

What's Douglas Baker's mailing address?

Douglas's mailing address filed with the SEC is 400 WATER STREET, SUITE 200, , ROCHESTER, MI, 48307.

Insiders trading at OptimizeRx Corp

Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff et David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.

What does OptimizeRx Corp do?

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.

Complete history of Mr. Baker stock trades at OptimizeRx Corp

OptimizeRx Corp executives and stock owners

OptimizeRx Corp executives and other stock owners filed with the SEC include:

• Stephen Silvestro,
  Chief Commercial Officer
• William Febbo,
  Chief Executive Officer, Director
• William J. Febbo,
  CEO & Director
• Stephen L. Silvestro,
  Chief Commercial Officer
• Miriam Paramore,
  President
• Douglas Baker,
  Chief Financial Officer
• Gus Halas,
  Chairman of the Board
• Lynn Vos,
  Independent Director
• Patrick Spangler,
  Independent Director
• James Lang,
  Independent Director
• Angelo Campano,
  Senior Vice President - Principal of Agency Channels
• Ron Both,
  Investor Relations
• Gregory Wasson,
  Director
• Todd Inman,
  Chief Technology Officer
• Maira Alejandra,
  Media Relations Mang.
• Todd Inman,
  Chief Technology Officer
• Andrew Jacob D'Silva,
  Sr. VP of Corp. Fin.
• Douglas P. Baker,
  Exec. VP of Fin. & Accounting
• Edward Stelmakh C.M.A., M.B.A., MBA,
  CFO & COO
• Rebecca Whitney,
  Sr. VP of Commercial Operations
• Terence J. Hamilton,
  Sr. VP of Pharma
• Sheryl Kearney,
  HR Mang.
• Marion K Odence-Ford,
  Gen. Counsel & Chief Compliance Officer
• Cathy Klema,
  Director
• Ellen O'connor Vos,
  Director
• Plc Wpp Luxembourg Gamma Th...,
  
• Investment Company, Inc. Awm,
  10% owner
• Bradley Louis Radoff,
  10% owner
• Jack T Pinney,
  Director
• Richard Kraniak,
  10% owner
• David Lester,
  Chairman of the Board
• David Harrell,
  Chief Executive Officer
• Terrence Hamilton,
  Vice President
• James M Brooks,
  SVP of Business Development
• Brian J Dillon,
  SR. VP OF PRODUCT & STRATEGY
• Brian Clark Mc Carthy,
  Chief Revenue Officer
• Marion Odence Ford,
  General Counsel and CCO
• Edward Stelmakh,
  CFO/COO
• Doug Besch,
  Chief Product Officer
• Theresa Greco,
  Chief Commercial Officer